Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.74 |
| ▸ | PSMB1 | P20618 | 7/20 | 0.72 |
| ▸ | PSMB5 | P28074 | 6/20 | 0.72 |
| ▸ | LTA4H | P09960 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | PSMB2 | P49721 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | ESRRG | P62508 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7597039 | 0.90 | ESR1 (0.89) | ESR1PSMB1PSMB5LTA4HPSMB2 | |
| SCHEMBL7603635 | 0.89 | ESR1 (0.88) | ESR1PSMB1PSMB5LTA4HPSMB2 | |
| SCHEMBL7602297 | 0.86 | PSMB1 (0.78) | ESR1PSMB1PSMB5LTA4HSMN1; SMN2 | |
| SCHEMBL7598249 | 0.85 | ESR1 (1.00) | ESR1PSMB1PSMB5LTA4HPSMB2 | |
| SCHEMBL7598246 | 0.85 | ESR1 (1.00) | ESR1PSMB1PSMB5LTA4HPSMB2 | |
| SCHEMBL15647618 | 0.84 | PSMB1 (1.00) | ESR1PSMB1PSMB5SMN1; SMN2GAA | |
| SCHEMBL13305493 | 0.84 | PSMB1 (0.79) | ESR1PSMB1PSMB5LTA4HSMN1; SMN2 | |
| SCHEMBL23266951 | 0.81 | PSMB1 (0.87) | ESR1PSMB1PSMB5LTA4HPSMB2 | |
| SCHEMBL8471455 | 0.80 | LTA4H (0.62) | ESR1PSMB1PSMB5LTA4HSMN1; SMN2 | |
| SCHEMBL8472085 | 0.80 | LTA4H (0.62) | ESR1PSMB1PSMB5LTA4HSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020161007-A1 | Non-steroidal modulators of estrogen receptors | PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2002-10-31 | — | — | US | claimed |
| US-20020161007-A1 | Non-steroidal modulators of estrogen receptors | PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161007-A1 | Non-steroidal modulators of estrogen receptors | ESRRB, ESR2, ESRRG | ESR1 6/4885PSMB1 1502/4885PSMB5 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.